Related Experiment Videos
New vistas in chronic schizophrenia
F Lichtigfeld1, R Sandyk, M Gillman
1South African Brain Research Institute, Johannesburg.
The International Journal of Neuroscience
|February 1, 1988
Summary
Disturbed glucose regulation in chronic schizophrenia may be linked to cAMP/cGMP imbalance. Enhancing the cGMP system with insulin and D-ribose may improve treatment outcomes for this condition.
Area of Science:
- Neuroscience
- Biochemistry
- Psychiatry
Background:
- Chronic schizophrenia is associated with disturbed glucose regulation in key brain areas.
- Imbalances in cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling are implicated in schizophrenia's pathology.
- Current treatments for schizophrenia often face challenges with intractable cases.
Purpose of the Study:
- To explore the role of glucose regulation and cAMP/cGMP balance in chronic schizophrenia.
- To propose therapeutic strategies targeting these metabolic pathways for improved treatment outcomes.
Main Methods:
- Review of existing literature on glucose metabolism and second messenger systems in schizophrenia.
- Hypothesizing the dysregulation of cAMP and cGMP generating systems.
- Suggesting therapeutic interventions to restore metabolic balance.
Main Results:
- Evidence suggests dysregulated glucose metabolism in the frontal cortex and basal ganglia of schizophrenia patients.
- A potential imbalance favoring cAMP over cGMP activity is proposed as a mechanism for the condition.
- Therapeutic strategies enhancing the cGMP system are suggested.
Conclusions:
- Restoring normal metabolic integrity by enhancing the cGMP generating system is crucial for treating chronic schizophrenia.
- High-dose insulin with hyperglycemia and D-ribose supplementation show promise as adjunctive therapies.
- These approaches could enhance the efficacy of existing medications for intractable schizophrenia.